Clinical Trials Logo
  1. Home
  2. Pancreatic Cancer Non-resectable
  3. NCT03590275

Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX — HOPE  

Pancreatic Cancer Non-resectable Clinical Trial

Official title:
Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX

Clinical Trial Summary

The aim of this study is to identify new prognostic factors in patients affected by advanced pancreatic carcinoma treated with first line chemotherapy with FOLFIRINOX regimen. Primary objective is the identification of clinical, laboratory and pathologic factors affecting overall survival of these patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03590275
Study type Observational
Source Azienda Ospedaliero, Universitaria Pisana
Contact
Status Completed
Phase
Start date October 2, 2017
Completion date June 30, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02128100 - Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT05047991 - Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Phase 2
Recruiting NCT05265663 - Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients N/A
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06160323 - Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer N/A
Active, not recruiting NCT04156087 - Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT06387368 - Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer Phase 4
Active, not recruiting NCT03941093 - Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer Phase 3
Recruiting NCT03165591 - Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05549414 - Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System N/A
Recruiting NCT06388967 - Pancreatic Cancer Detection Consortium
Not yet recruiting NCT06375967 - EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) N/A
Withdrawn NCT04852367 - PanDox: Targeted Doxorubicin in Pancreatic Tumours Phase 1
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Recruiting NCT03964064 - I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer N/A
Not yet recruiting NCT06361030 - Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT05424159 - Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer N/A
Terminated NCT01887041 - Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer Phase 4
Active, not recruiting NCT03984214 - Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer Phase 3
Recruiting NCT05262452 - Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer N/A